195 related articles for article (PubMed ID: 27653861)
1. Interleukins 17 and 10 in a sample of Egyptian relapsing remitting multiple sclerosis patients.
Tawfik TZ; Gad AH; Mehaney DA; El Nahrery E; Shehata HS; Hashem H; Ghaffar NFA; Shalaby N
J Neurol Sci; 2016 Oct; 369():36-38. PubMed ID: 27653861
[TBL] [Abstract][Full Text] [Related]
2. Micro-RNA-96 and interleukin-10 are independent biomarkers for multiple sclerosis activity.
Sedeeq MS; El-Nahrery EMA; Shalaby N; Hussein M; Shehata H; El Aal RA; Abdel Ghaffar NF; Mohamed MM
J Neurol Sci; 2019 Aug; 403():92-96. PubMed ID: 31238191
[TBL] [Abstract][Full Text] [Related]
3. Circulating levels of interleukin-17A, tumor necrosis factor-alpha, interleukin-18, interleukin-10, and cognitive performance of patients with relapsing-remitting multiple sclerosis.
Trenova AG; Slavov GS; Draganova-Filipova MN; Mateva NG; Manova MG; Miteva LD; Stanilova SA
Neurol Res; 2018 Mar; 40(3):153-159. PubMed ID: 29297273
[TBL] [Abstract][Full Text] [Related]
4. An Intricate Mechanism of Action of Avonex in Relapsing Remitting Multiple Sclerosis Patients: Variation of Serum Titre of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-β.
Balasa R; Maier S; Voidazan S; Hutanu A; Bajko Z; Motataianu A
CNS Neurol Disord Drug Targets; 2015; 14(6):804-10. PubMed ID: 25801840
[TBL] [Abstract][Full Text] [Related]
5. Clinical and laboratory study of pro-inflammatory and antiinflammatory cytokines in women with multiple sclerosis.
Trenova AG; Manova MG; Kostadinova II; Murdjeva MA; Hristova DR; Vasileva TV; Zahariev ZI
Folia Med (Plovdiv); 2011; 53(2):29-35. PubMed ID: 21797104
[TBL] [Abstract][Full Text] [Related]
6. Micro-RNA 18b and interleukin 17A profiles in relapsing remitting multiple sclerosis.
Mohamed MS; Nahrery EMAE; Shalaby N; Hussein M; Aal RAE; Mohamed MM
Mult Scler Relat Disord; 2019 Feb; 28():226-229. PubMed ID: 30623862
[TBL] [Abstract][Full Text] [Related]
7. The role of Th17 cells in patients with relapsing-remitting multiple sclerosis: interleukin-17A and interleukin-17F serum levels.
Babaloo Z; Aliparasti MR; Babaiea F; Almasi S; Baradaran B; Farhoudi M
Immunol Lett; 2015 Apr; 164(2):76-80. PubMed ID: 25625963
[TBL] [Abstract][Full Text] [Related]
8. [Change of interleukin-4 and interleukin-12 levels after therapy of multiple sclerosis relapse with methylprednisolone].
Bartosik-Psujek H; Magryś A; Montewka-Kozioł M; Stelmasiak Z
Neurol Neurochir Pol; 2005; 39(3):207-12. PubMed ID: 15981158
[TBL] [Abstract][Full Text] [Related]
9. CXCL11 (Interferon-inducible T-cell alpha chemoattractant) and interleukin-18 in relapsing-remitting multiple sclerosis patients treated with methylprednisolone.
Szczuciński A; Kalinowska A; Losy J
Eur Neurol; 2007; 58(4):228-32. PubMed ID: 17827967
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-Beta1 Serum Titers in Relapsing Remitting Multiple Sclerosis Patients Treated with Avonex, Possible Biomarkers for Treatment Response.
Balasa R; Maier S; Voidazan S; Hutanu A; Bajko Z; Motataianu A; Tilea B; Tiu C
CNS Neurol Disord Drug Targets; 2017; 16(1):93-101. PubMed ID: 27306062
[TBL] [Abstract][Full Text] [Related]
11. Alterations in serum levels of IL-17 in contrast to TNF-alpha correspond to disease-modifying treatment in relapsing-remitting multiple sclerosis.
Trenova AG; Slavov GS; Manova MG; Draganaova-Filipova MN; Mateva NG; Miteva LD; Stanilova SA
Scand J Clin Lab Invest; 2017 Jul; 77(4):283-288. PubMed ID: 28319417
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab Changes the Peripheral Profile of the Th17 Panel in MS Patients: New Mechanisms of Action.
Balasa RI; Simu M; Voidazan S; Barcutean LI; Bajko Z; Hutanu A; Simu I; Maier S
CNS Neurol Disord Drug Targets; 2017; 16(9):1018-1026. PubMed ID: 28782487
[TBL] [Abstract][Full Text] [Related]
13. Effect of treatment with methylprednisolone on the serum levels of IL-12, IL-10 and CCL2 chemokine in patients with multiple sclerosis in relapse.
Rentzos M; Nikolaou C; Rombos A; Evangelopoulos ME; Kararizou E; Koutsis G; Zoga M; Dimitrakopoulos A; Tsoutsou A; Sfangos C
Clin Neurol Neurosurg; 2008 Dec; 110(10):992-6. PubMed ID: 18657352
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-β.
Bălaşa R; Bajko Z; Huţanu A
Mult Scler; 2013 Jun; 19(7):885-90. PubMed ID: 23207971
[TBL] [Abstract][Full Text] [Related]
15. The role of endogenous antiradical protective system in multiple sclerosis.
Davitashvili D; Beridze M; Shakarishvili R; Kiziria M; Sanikidze T
Georgian Med News; 2012 Apr; (205):11-9. PubMed ID: 22665726
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-17A Levels Vary in Relapsing-Remitting Multiple Sclerosis Patients in Association with Their Age, Treatment and the Time of Evolution of the Disease.
Guerrero-García Jde J; Castañeda-Moreno VA; Torres-Carrillo N; Muñoz-Valle JF; Bitzer-Quintero OK; Ponce-Regalado MD; Mireles-Ramírez MA; Valle Y; Ortuño-Sahagún D
Neuroimmunomodulation; 2016; 23(1):8-17. PubMed ID: 26599431
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor-alfa and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis.
Obradović D; Kataranovski M; Dincić E; Obradović S; Colić M
Vojnosanit Pregl; 2012 Feb; 69(2):151-6. PubMed ID: 22500369
[TBL] [Abstract][Full Text] [Related]
18. Cytokines and disability in interferon-β-1b treated and untreated women with multiple sclerosis.
Trenova AG; Slavov GS; Manova MG; Kostadinova II
Arch Med Res; 2014 Aug; 45(6):495-500. PubMed ID: 25130430
[TBL] [Abstract][Full Text] [Related]
19. A clinical and laboratory study evaluating the profile of cytokine levels in relapsing remitting and secondary progressive multiple sclerosis.
Pasquali L; Lucchesi C; Pecori C; Metelli MR; Pellegrini S; Iudice A; Bonuccelli U
J Neuroimmunol; 2015 Jan; 278():53-9. PubMed ID: 25595252
[TBL] [Abstract][Full Text] [Related]
20. Cytokine profile in relapsing‑remitting multiple sclerosis patients and the association between progression and activity of the disease.
Kallaur AP; Oliveira SR; Colado Simão AN; Delicato de Almeida ER; Kaminami Morimoto H; Lopes J; de Carvalho Jennings Pereira WL; Marques Andrade R; Muliterno Pelegrino L; Donizete Borelli S; Kaimen-Maciel DR; Reiche EM
Mol Med Rep; 2013 Mar; 7(3):1010-20. PubMed ID: 23292766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
